Impact of medical treatment of endometriosis on bone mass

Article Abstract:

Treatment with certain types of hormones may increase the risk of bone loss in women suffering from endometriosis. Endometriosis is a disorder characterized by the growth of tissue resembling the endometrium, or the lining of the uterus, in other parts of the pelvic cavity. A review of the medical literature found that treatment with gonadotrophin-releasing hormone agonists may reduce bone mineral density significantly in some women with endometriosis. This decrease in bone mineral density may occur within three months of beginning treatment. The reduction in bone mineral density was greater in women who were given a depot injection than in those treated with intranasal spray. Treatment with progestins may prevent or reduce the rate of bone mineral loss in women treated with gonadotrophin-releasing hormone agonists.

Bones, Bone density, Gonadotropin releasing hormone, Gonadorelin

---

Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis

Article Abstract:

Gestrinone may effectively treat endometriosis while preserving bone density. Endometriosis is a complication of menstruation where menstrual tissue becomes implanted outside the uterus. Researchers measured the effectiveness of two different doses of gestrinone on 11 patients with endometriosis. The 2.5 mg twice a week dose of gestrinone significantly reduced the number of endometriosis implants and was more effective than the 1.5 mg twice a week dose in treating mild to moderate endometriosis. The 2.5 mg dose increased spinal bone mass by 7.1% whereas the 1.5 mg dose decreased spinal bone mass by 7.1%.

Hormone therapy

---

Oxytocin receptor and its messenger ribonucleic acid in human leiomyoma and myometrium

Article Abstract:

Oxytocin and its receptor are present in uterine leiomyomas. These benign tumors are often called fibroids. Researchers tested tissue samples of uterine leiomyomas and the adjacent normal tissue from 20 women for the presence of oxytocin and its receptor. Both types of tissues tested positive and the concentration of oxytocin was higher during the pre-ovulatory phase of the menstrual cycle than during the post-ovulatory phase. The presence of the oxytocin receptor allows the tumor to be regulated by estrogen and progesterone.

Myometrium, Oxytocin, Uterine fibroids

Similar abstracts:

• Abstracts: Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells
• Abstracts: The influence of fat free mass on prediction of densitometric body composition by bioelectrical impedance analysis and by anthropometry
• Abstracts: Annual update of how each state stands on legislative issues affecting advanced nursing practice
• Abstracts: Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS: a preliminary report
• Abstracts: Hip involvement in early rheumatoid arthritis. Increased concentrations of bone sialoprotein in joint fluid after knee surgery

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.